

KOBO BIOTECH LIMITED

Corp. Office: Unit 104, Hyde Park, Saki Vihar Road,
Opp. Ansa Industrial Estate, Andheri (E), Mumbai - 400 072
Tel.: +91-22 4287 1210 • Fax: +91-22-4287 1285
E-mail: info@kobobiotech.com • Website: www.kobobiotech.com
(CIN : L24110TG1993PLC16112)

Asst. General Manager,
Dept. of Corporate Services.
Bombay Stock Exchange Limited,
14th Floor, P.J.Towers, Dalal Street, Fort,
Mumbai: 400 001

30th May, 2024

Dear Sir/ Madam,

Scrip Name: Kobo Biotech Limited, Scrip Code: 531541

Sub: OUTCOME OF THE BOARD MEETING: audited Financial results for the Quarter and year ended 31st March, 2024.

This is to inform you that the Board of Directors of Kobo Biotech Limited at their meeting held today i.e. on Thursday, 30th May, 2024 inter alia approved the audited financial results for the Quarter and the year ended 31st March, 2024 alongwith the report of statutory auditor thereon.

Please find enclosed a copy of the audited Financials along with audit report from the Statutory Auditors.

The above-referred meeting was commenced at 03:00 p.m. and concluded at 3:45 p.m.

The above is pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, for your information and record.

Thank you,
For Kobo Biotech Limited

Jignesh Patel
Company Secretary

KOBO BIOTECH LIMITED

Corp. Office: Unit 104, Hyde Park, Saki Vihar Road,
Opp. Ansa Industrial Estate, Andheri (E), Mumbai - 400 072
Tel.: +91-22 4287 1210 • Fax: +91-22-4287 1285
E-mail: info@kobobiotech.com • Website: www.kobobiotech.com
(CIN : L24110TG1993PLC16112)

DECLARATION

[Pursuant to Regulation 33 (3)(d) of SEBI (Listing Obligation and Disclosure Requirement) (Amendment) Regulations, 2016]

I, Ajit Kamath, Director of Kobo Biotech Limited, having its Corporate Office at H Wing, 4th Floor, Tex Centre, Chandivali, Andheri(E), Mumbai 400 072, Maharashtra, do hereby declare that The Statutory Auditors of the Company, M/s. A N Shah & Associates, Chartered Accountants, have issued an Audit Reports with unmodified opinion on the Annual Audited Financial Results of the Company (Standalone and Consolidated) for the Financial Year ended March 31, 2024. This declaration is being made pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Yours sincerely,
For Kobo Biotech Limited

Ajit Kamath
Director

Mumbai
30-05-2024



A N Shah & Associates
Chartered Accountants

C/303, Anand Nagar,
Forjett Street,
Opp. Bhatia Hospital,
Mumbai – 400 036.
Tel: +91 22 4976 9085

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of Kobo Biotech Limited
Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of Kobo Biotech Limited (the "Company") for the quarter ended March 31, 2024 and for the year ended March 31, 2024 ("Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- a) Is presenting accordance with the requirements of the Listing Regulations in this regard; and
- b) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India, of the net profit and total comprehensive Income and other financial information of the Company for the quarter ended March 31, 2024 and for the year ended March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

A N Shah & Associates
Chartered Accountants



C/303, 3rd Floor, Anand Nagar, Forjett Street, opposite Bhatia Hospital, Mumbai – 400 036.
Landline No: +91 22 4976 9085, Mobile - +91 96190 40158
Email id: ca.akashshah3033@gmail.com



Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive profit of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone Financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial result as a whole is free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

A N Shah & Associates
Chartered Accountants

C/303, 3rd Floor, Anand Nagar, Forjett Street, opposite Bhatia Hospital, Mumbai – 400 036
Landline No: +91 22 4976 9085, Mobile - +91 96190 40158
Email id: ca.akashshah3033@gmail.com





A N Shah & Associates
Chartered Accountants

C/303, Anand Nagar,
Forjett Street,
Opp. Bhatia Hospital,
Mumbai – 400 036.
Tel: +91 22 4976 9085

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.
- Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

A N Shah & Associates
Chartered Accountants

C/303, 3rd Floor, Anand Nagar, Forjett Street, opposite Bhatia Hospital, Mumbai – 400 036.
Landline No: +91 22 4976 9085, Mobile - +91 96190 40158
Email id: ca.akashshah3033@gmail.com





A N Shah & Associates
Chartered Accountants

C/303, Anand Nagar,
Forjett Street,
Opp. Bhatia Hospital,
Mumbai – 400 036.
Tel: +91 22 4976 9085

Other Matter

The Statement includes the results for the quarter ended March 31, 2024 and March 31, 2023 being the balancing figure between the audited figures in respect figures of the full financial year ended, and the published year-to-date figures up to the third quarter of the respective financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For A N SHAH & ASSOCIATES
Chartered Accountants
ICAI Firm Registration Number: 152559W

AKASH SHAH
Proprietor
Membership Number: 191340
UDIN: 24191340BKECKM1229



Place: Mumbai
Dated: 30th May, 2024

A N Shah & Associates
Chartered Accountants

C/303, 3rd Floor, Anand Nagar, Forjett Street, opposite Bhatia Hospital, Mumbai – 400 036.
Landline No: +91 22 4976 9085, Mobile - +91 96190 40158
Email id: ca.akashshah3033@gmail.com

KOBO BIOTECH LIMITED

CIN: L24110TG1993PLC016112

Regd. Office: Plot No. 121A/1, Western Hills, Addagutta Society, Opp. JNTU, Kukatpally, Hyderabad - 500072
Corp. Office : Unit 101/104, Hyde Park, Saki Vihar Road, Andheri (E), Mumbai - 400 072

Statement of Audited Financial Results for the quarter and Year ended 31st March, 2024

(Amount in INR Lakhs)

Sr.No.	PARTICULARS	Quarter Ended			Year Ended	
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Income from operations	0.00	0.00	0.00	0.00	0.00
II	Other Income	0.00	0.00	0.00	1.52	1.52
III	Total Income (I+II)	0.00	0.00	0.00	1.52	1.52
IV	Expenditure					
	(a) Cost of raw material consumed	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	(c) Employee benefits expense	6.72	6.51	6.02	24.80	23.01
	(d) Finance Cost	0.00	0.01	0.02	0.01	0.02
	(e) Depreciation and Amortisation expenses	101.12	102.78	100.30	407.14	407.19
	(f) Other Expenses	17.78	13.83	73.00	62.45	126.64
	Total Expenses	125.62	123.13	179.34	494.40	556.86
V	Profit (Loss) before Exceptional Items and Tax (III-IV)	(125.62)	(123.13)	(179.34)	(492.88)	(555.34)
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00
VII	Profit (Loss) before Tax (V-VI)	(125.62)	(123.13)	(179.34)	(492.88)	(555.34)
VIII	Tax expenses					
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00
IX	Net Profit (Loss) after tax (VII-VIII)	(125.62)	(123.13)	(179.34)	(492.88)	(555.34)
X	Other Comprehensive Income					
	(i) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX+X)	(125.62)	(123.13)	(179.34)	(492.88)	(555.34)
XII	Paid-up equity share capital	2,382.50	2,382.50	2,382.50	2,382.50	2,382.50
XIII	Other Equity					(15,180.65)
XIV	Earnings Per Share (Basic and Diluted) (in Rs)	(0.53)	(0.52)	(0.75)	(2.07)	(2.33)

Notes:

- The above audited standalone financial results, prepared in accordance with the Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 and guidelines issued by the Securities and Exchange Board of India, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30th May, 2024.
- The Company operates only in one Business Segment i.e. manufacturing Active Pharmaceutical Ingredients (API)/ Bulk Drugs.
- The number of investor complaints at the beginning and pending at the end of the Quarter were Nil.
- Figures for the quarter ended 31st March are the balancing figures between the audited figures in respect of full financial year and the published year-to-date figures upto the third quarter of the relevant financial year, which were subjected to limited review
- Figures of the previous periods have been regrouped / rearranged wherever considered necessary.

By order of the Board
For **KOBO BIOTECH LIMITED**



Ajit Kamath
Director

Mumbai
30-05-2024

KOBO BIOTECH LIMITED

CIN: L24110TG1993PLC016112

BALANCE SHEET AS AT 31st MARCH, 2024

(Amount in INR Lakhs)

Particulars	31.03.2024	31.03.2023
ASSETS		
Non-Current Assets		
(a) Property, Plant and Equipment	3,351.60	3,758.74
(b) Capital Work-in-Progress	0.00	0.00
(c) Investment Property	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible Assets	0.00	0.00
(f) Intangible Assets Under Development	0.00	0.00
(g) Financial Assets	0.00	0.00
(i) Investments	0.00	0.00
(ii) Trade Receivables	0.00	0.00
(ii) Loans	0.00	0.00
(ii) Others	0.00	0.00
(e) Deferred Tax Asset (Net)	0.00	0.00
(d) Other Non-Current Assets	0.00	0.00
	3,351.60	3,758.74
Current assets		
(a) Inventories	1,804.05	1,804.05
(b) Financial Assets		
(i) Investments	0.00	0.00
(ii) Trade Receivables	1,196.54	1,195.24
(iii) Cash and Cash Equivalents	13.77	8.41
(iv) Bank Balances Other than (iii) above	4.29	4.29
(v) Loans		
(vi) Others	51.53	51.84
(c) Current Tax Assets (Net)	571.90	571.75
(c) Other Current Assets	145.67	138.69
	3,787.75	3,774.27
TOTAL	7,139.35	7,533.01
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	2,382.50	2,382.50
(b) Other Equity	(15,673.53)	(15,180.65)
	(13,291.03)	(12,798.15)
Liabilities		
Non Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	3,171.40	3,266.00
(ii) Trade Payables		
Micro, Small and Medium Enterprises	0.00	0.00
Others	0.00	0.00
(ii) Other Financial Liabilities	0.00	0.00
(b) Provisions	177.74	177.74
(c) Deferred Tax liabilities (Net)	299.01	299.01
(c) Other Non-Current Liabilities		
	3,648.15	3,742.75
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	10,797.71	10,718.11
(ii) Trade Payables		
Micro, Small and Medium Enterprises	0.00	1.03
Others	5,578.05	5,472.48
(iii) Other Financial Liabilities		
(b) Other Current Liabilities	385.56	377.41
(c) Provisions	0.00	0.00
(d) Current Tax Liabilities (Net)	20.91	19.38
	16,782.23	16,588.41
TOTAL	7,139.35	7,533.01

For KOBO BIOTECH LIMITED



Mumbai
30-05-2024Ajit Kamath
Director

CASH FLOW STATEMENT FOR THE YEAR ENDED 31st March 2024

(Amount in INR Lakhs)

Particulars	For the year ended 31st March, 2024	For the year ended 31st March, 2023
A. Cash Flow from Operating Activities		
Net Profit before tax and extraordinary items	(492.88)	(555.34)
Adjustments for		
Depreciation	407.14	407.19
Interest	0.00	0.00
Operating Profits before Working Capital Changes	(85.74)	(148.15)
Increase / (Decrease) in Trade Payables	104.54	256.28
(Increase) / Decrease in Inventories	0.00	0.00
(Increase) / Decrease in Trade Receivables	(1.30)	(15.62)
Increase / (Decrease) in Other Current Liabilities	9.69	0.94
(Increase) / Decrease in other Financial assets	(6.83)	(5.99)
Cash Generated from Operations	20.36	87.46
Income Tax		
Net Cash flow from operating Activities (A)	20.36	87.46
B. Cash Flow from Investing Activities		
Proceeds from sales/Disposal of investments	0.00	0.00
Proceeds from sales/Disposal of fixed assets	0.00	0.00
Net proceeds /Disposals from advances	0.00	0.00
Net Cash Used in Investing Activities (B)	0.00	0.00
C. Cash Flow from Financing Activities		
Proceeds from Long -term borrowings	79.60	0.00
Proceeds from non current liabilities	(94.60)	(87.40)
Proceeds from short -term borrowings	0.00	0.00
Interest	0.00	0.00
Net Cash inflow from Financing Activities (C)	(15.00)	(87.40)
Net Increase/(Decrease) in Cash Flow (A+B+C)	5.36	0.06
Opening Balance of Cash and Cash Equivalent	12.69	12.63
Closing Balance of Cash and Cash Equivalent	18.05	12.69

For KOBO BIOTECH LIMITED



Ajit Kamath
Director

Mumbai
30-05-2024